Over the recent years, the global Hepatitis B Treatment industry has been driven by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infection, improving surveillance and diagnostic facilities, significant number of drugs in pipeline with better efficacy coupled with emerging vaccines with lower dosage and better effectiveness. Globally, the growth in Hepatitis B Treatment market is driven by backed by growing middle class population group demanding better drugs to improve lifestyle.
Market Analysis and Insights: Global and United States Hepatitis B Virus (HBV) Market
This report focuses on global and United States Hepatitis B Virus (HBV) market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Hepatitis B Virus (HBV) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, Therapeutics accounting for % of the Hepatitis B Virus (HBV) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Among the type of treatment, therapeutics accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with chronic Hepatitis B virus with unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.
Global Hepatitis B Virus (HBV) Scope and Market Size
Hepatitis B Virus (HBV) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Hepatitis B Virus (HBV) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Hepatitis B Virus (HBV) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Therapeutics
Vaccine
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Merck
Gilead Sciences
Novartis
GlaxoSmithKline
Hoffmann
La Roche
Bristol-Myers Squibb